Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service lumbar fusion cases in Arkansas: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (239 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 25 | 1,029 | 29% |
| 2020 | 26 | 911 | 32% |
| 2021 | 25 | 975 | 37% |
Posterolateral, interbody, and anterior lumbar fusion with instrumentation. Professional codes (what the surgeon bills): CPT 22612, 22630, 22633, 22558; the hospital bills MS-DRG 453, 454, 455, 459, 460, 402, 426, 427, 428, 447, 448, 450, 451, 523, 524, 525.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 66% of the cases CMS names in Arkansas; 16 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Decompression & minimally invasive spine | 30 | 1,254−7.9%/yr | −7.9%/yr | 3.21.0× | 7% | 1,220 in 2030−0.4%/yr |
| Kyphoplasty & vertebroplasty |
Lumbar fusion in every state, and its device makers · Every procedure market in Arkansas · Every state · Compare with Texas
| 2024 |
| 751 |
| 49% |
| 2025 est. | ≈ 720 | – |
| 2026 est. | ≈ 720 | – |
| 2022 | 24 | 908 | 40% |
| 2023 | 18 | 815 | 46% |
| 2024 | 24 | 751 | 49% |
| 2025 from claims | – | 721 583–847 | 50% |
| 2026 forecast | – | 723 566–908 | 51% |
| 2027 forecast | – | 724 537–957 | 51% |
| 2028 forecast | – | 726 514–1,002 | 52% |
| 2029 forecast | – | 727 494–1,042 | 53% |
| 2030 forecast | – | 728 477–1,080 | 53% |
In 2025, 53% inpatient hospital, 41% hospital outpatient, 5% surgery center. The share outside the hospital has moved +5 pts since 2019, so more of this market is decided in surgery centers and offices each year.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| +0.8%/yr |
| 3.2 |
| 7% |
| 9,130 in 2030+3.7%/yr |
| North Carolina | 81 | 3,107−4.5%/yr | −4.5%/yr | 3.0 | 0% | 3,140 in 2030+0.2%/yr |
| Georgia | 75 | 3,096−2.3%/yr | −2.3%/yr | 3.4 | 3% | 3,640 in 2030+2.7%/yr |
| Virginia | 72 | 3,069−1.3%/yr | −1.3%/yr | 2.9 | 0% | 3,830 in 2030+3.8%/yr |
| Tennessee | 71 | 2,726+1.2%/yr | +1.2%/yr | 3.7 | 0% | 3,030 in 2030+1.8%/yr |
| Maryland | 58 | 2,364−2.2%/yr | −2.2%/yr | 2.6 | 5% | 2,480 in 2030+0.8%/yr |
| South Carolina | 56 | 2,015−1.3%/yr | −1.3%/yr | 2.8 | 1% | 2,510 in 2030+3.8%/yr |
| Louisiana | 39 | 1,859+1.8%/yr | +1.8%/yr | 4.4 | 0% | 2,180 in 2030+2.7%/yr |
| Oklahoma | 45 | 1,762−4.7%/yr | −4.7%/yr | 3.5 | 1% | 1,970 in 2030+1.9%/yr |
| Alabama | 41 | 1,657−1.3%/yr | −1.3%/yr | 3.6 | 2% | 1,880 in 2030+2.1%/yr |
| Kentucky | 33 | 1,251−4%/yr | −4%/yr | 2.6 | 1% | 1,500 in 2030+3.1%/yr |
| Mississippi | 14 | 679−5.9%/yr | −5.9%/yr | 1.8 | 0% | 520 in 2030−4.5%/yr |
| Delaware | 12 | 599−2.6%/yr | −2.6%/yr | 3.4 | 10% | 670 in 2030+2%/yr |
| District of Columbia | 8 | 338+2.1%/yr | +2.1%/yr | 5.2 | 3% | 370 in 2030+1.6%/yr |
| West Virginia | 9 | 303−1.5%/yr | −1.5%/yr | 1.4 | 0% | 330 in 2030+1.5%/yr |
| 11 |
| 674−8.7%/yr |
| −8.7%/yr |
| 1.81.0× |
| 37% |
| 540 in 2030−3.7%/yr |
| Cervical fusion & disc arthroplasty | 15 | 594−6.2%/yr | −6.2%/yr | 1.50.9× | 5% | 650 in 2030+1.4%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Medtronic leads with 88% of company spending on these surgeons in 2025, level with 2024.
In 2025, 15 companies reported engagement with Arkansas’s surgeons worth $159K in consulting, speaking, meals and travel tied to these products, about $6,625 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 87 clearances and approvals in the category, 12 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.